Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

Recurrent Glioblastoma Clinical Trial

Official title:

A Phase II Trial of Enzastaurin in Combination With Bevacizumab in Adults With Recurrent Malignant Gliomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00586508
• Other study ID #: 11394
• Secondary ID: H6Q-MC-S033
• Status: Completed
• Phase: Phase 2
• Start date: November 2007
• Est. completion date: October 2013

Study information

• Verified date: September 2020
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate both enzastaurin and bevacizumab in the treatment of recurrent malignant gliomas.

Other known NCT identifiers

• NCT00559923

Recruitment information / eligibility

• Status: Completed
• Enrollment: 81
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant must be at least 18 years old

• Participant must have been diagnosed with a recurrent brain tumor by magnetic resonance imaging (MRI) scan

• Participant must be willing to practice adequate contraception

• Participant must be able to swallow the enzastaurin tablets whole and receive bevacizumab intravenously

• Participant must agree to use the study drug only as instructed by your study doctor and staff.

Exclusion Criteria:

• Women who are pregnant or breastfeeding

• Participants who have significant heart, liver, kidney, or psychiatric disease

• Participants who have an active infection

• Participants who have any recent bleeding in the brain

• Participants who are taking any anti-coagulation or anti-platelet medication [including aspirin, non-steroidal anti-inflammatories, Cyclooxygenase-2 (COX-2) inhibitors]

Related Conditions & MeSH terms

• Glioblastoma
• Glioma
• Recurrent Glioblastoma

Intervention

Drug:
• enzastaurin
1125 milligrams (mg) loading dose then 500 or 875 mg, orally, daily, 4-week cycles with participants evaluated after each cycle. The dose difference is for participants who are on enzyme-inducing antiepileptic drugs (EIAED) versus non-enzyme inducing antiepileptic drugs (NEIAED).
• bevacizumab
10 milligrams per kilogram (mg/kg), intravenously (IV), every 2 weeks, participants are evaluated after each cycle (4-week cycles).
• Enzyme-inducing antiepileptic drugs (EIAED)
Administered orally
• Non-enzyme inducing antiepileptic drugs (NEIAED)
Administered orally

Locations

Country	Name	City	State
United States	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Bethesda	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Eli Lilly and Company	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-Free Survival at 6 Months (PFS-6)	Data presented are the percentage of participants without progressive disease (PD) or death from any cause 6 months after registration. PD was a 25% increase in the sum of products of all measurable lesions (or 2 largest lesions if too numerous) over the smallest sum observed (over baseline if no decrease) or clear worsening of any evaluable disease, or appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer).	Registration to 6 months
Primary	Time to Progressive Disease (PD)	Defined as the time from registration to PD, death or date of last contact. PD was a 25% increase in the sum of products of all measurable lesions (or 2 largest lesions if too numerous) over the smallest sum observed (over baseline if no decrease) or clear worsening of any evaluable disease, or appearance of any new lesion/site, or failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to this cancer). Participants who had no PD or death at the time of the data inclusion cutoff, time to PD was censored at their last tumor assessment prior to the cutoff date.	Registration to PD, death or date of last contact up to 66.56 months
Primary	Number of Participants With Adverse Events (AEs) or Deaths (Safety)	Data presented are the number of participants who experienced serious adverse events (SAEs), other non-serious AEs and deaths during the study including the 30-day follow-up. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Event module.	Registration to study completion up to 67.56 months
Secondary	Overall Response Rate (ORR)	Overall response is confirmed complete response (CR) + partial response (PR). CR is complete disappearance of all measurable and evaluable disease, no new lesions, and no evidence of non-evaluable disease. PR is =50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions (or the 2 largest lesions), no progression of evaluable disease and no new lesions. ORR is calculated as (total number of participants with CR or PR from the start of registration until disease progression) / (the total number of participants treated)*100.	Registration to date of objective PD or death up to 66.56 months
Secondary	To Evaluate Tumor Markers and Genes		Baseline and every cycle (4-week cycles)
Secondary	Change From Baseline in Health-Related Quality of Life (HRQoL) Subscales	HRQoL was assessed with the Functional Assessment of Cancer Therapy - Brain (FACT-Br) version 4. The instrument consists of 50 items with a 5-point rating scale for each item, where 0 = "not at all" and 4 = "very much." Physical well-being, social/family well-being and functional well-being subscales consist of 7 items each with scores ranging from 0-28. The emotional well-being subscale consists of 6 items with a score ranging from 0-24. The brain cancer-specific subscale consists of 23 items with a score ranging from 0-92. Higher scores in each subscale represent better QoL. Changes from baseline in the 4 core subscales are presented.	Baseline, Cycles 1-12 (4-week cycles)

External Links

•   Lilly Clinical Trial Registry